Clinical trials
Malignancy clinical trials
Below are recruiting malignancy clinical trials, each written for real people, not researchers. We’re tracking 1,543 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Los Angeles, CaliforniaAges 1–21 - NCT07594626RecruitingPhase 1/Phase 2
BMS-986504 and Pemetrexed for Advanced Tumors With MTAP Loss
This trial tests a new drug (BMS-986504) combined with an existing chemotherapy (pemetrexed) for advanced solid cancers that have a specific genetic change called MTAP deletion. The trial aims to see if this combination can slow or stop tumor growth in patients whose cancer has progressed despite prior treatment.
Chicago, IllinoisAges 18 years+ - NCT07593209Recruiting
New PET scan tracer for detecting cancer using EphA2
This study tests a new radioactive tracer (a type of dye) called 68Ga-DOTA-EphA2 that helps PET scanners find cancer cells. Researchers want to see if this tracer can better identify tumors in patients who may have cancer.
Shenyang, LiaoningAges 18–80 - NCT07594496Enrolling by invitation
Cannabis Withdrawal in Blood Cancer Patients During Stem Cell Transplant
This study looks at whether patients with blood cancers who use cannabis experience withdrawal symptoms when hospitalized for stem cell transplant or CAR-T therapy (a type of immunotherapy). Understanding these symptoms could help doctors better support patients during treatment.
Scottsdale, ArizonaAges 18 years+ - NCT07583212RecruitingPhase 1
Phase 1 Trial of HRS-1635 for Relapsed B-Cell Blood Cancers
This early-stage trial tests a new drug called HRS-1635 in patients with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to previous treatment. The goal is to find the right dose and understand how well and safely the drug works.
Chengdu, SichuanAges 18 years+ - NCT06654440RecruitingPhase 2
Testing SHR-A2102 for advanced gynecological cancers
This trial tests a new targeted drug, SHR-A2102, for people with advanced gynecological cancers (like ovarian, uterine, or cervical) that have not responded to standard treatments. The drug is designed to deliver chemotherapy directly to cancer cells, which may help control the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07570563RecruitingPhase 1/Phase 2
T Cell Immunotherapy for Advanced Cancers
This study tests a new immunotherapy using specially engineered immune cells (called TCR-enhanced Vδ2 T cells) to treat blood cancers or solid tumors that haven't responded to standard treatments. The goal is to see if these cells can safely shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07574346RecruitingEarly Phase 1
IASO207 injection for relapsed or resistant B-cell lymphoma
This early-stage trial tests IASO207, a new injection designed to treat B-cell lymphomas (blood cancers) that have come back or stopped responding to standard treatments. The drug targets a protein called CD19 found on cancer cells.
BeijingAges 18–75 - NCT06597539Recruiting
PET scan to monitor immunotherapy in advanced liver cancer
This trial uses a special PET scan (68Ga-grazytracer) to see how well immunotherapy is working in people with advanced liver or bile duct cancer. The goal is to find a better way to monitor treatment response.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06644274Recruiting
PET scan for tracking immunotherapy in gastrointestinal cancers
This trial uses a special PET scan called 68Ga-grazytracer to see how well immunotherapy is working in people with stomach, colon, or other gastrointestinal cancers. The goal is to find out if this scan can help doctors track your response to treatment.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06728189RecruitingPhase 1
CD70-targeted CAR-NKT cells for advanced solid tumors
This trial tests a new type of immune cell therapy (CAR-NKT cells) that targets a protein called CD70 on cancer cells. It is for people with advanced solid tumors that have not responded to at least two prior treatments.
BeijingAges 18–75 - NCT06150469Recruiting
Inhaled aromatherapy for nausea from chemo
This trial tests if smelling a blend of essential oils can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. You would use a simple inhaler stick whenever you feel sick.
BrivéAges 18 years+ - NCT07561190Recruiting
Studying tumor biology in malignant pleural mesothelioma
This study collects and analyzes tumor samples from patients with malignant pleural mesothelioma (a cancer of the lung lining caused by asbestos exposure) to better understand the disease and find new treatment approaches. Researchers will examine your tumor at the molecular level to identify patterns that might help predict treatment outcomes.
CataniaAges 18 years+ - NCT07563829RecruitingPhase 1
NPX372 immunotherapy for advanced solid tumors
This trial tests NPX372, a new type of immunotherapy designed to fight several types of advanced cancer that haven't responded to standard treatments. It works by combining two immune signals to help your body's immune system recognize and attack cancer cells.
La Jolla, CaliforniaAges 19 years+ - NCT06732492RecruitingPhase 1
RD13-02 cell therapy for relapsed CD7+ NK/T lymphoma
This trial uses a new type of immune cell (RD13-02) to treat a rare and aggressive lymphoma that hasn't responded to other treatments. It targets cancer cells that carry a specific marker called CD7.
Wuhan, HubeiAges 3–70 - NCT07558304Recruiting
Comparing two stent placements for bile duct blockage from cancer
This trial compares two ways of placing a metal stent to open a blocked bile duct caused by cancer. The goal is to see which method works better and has fewer complications.
Porto Alegre, Rio Grande do SulAges 18 years+ - NCT07556822RecruitingPhase 1
Testing HRS-3005 for Blood Cancers That Have Returned
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT05615974RecruitingPhase 1/Phase 2
LM-101 injection study for advanced solid tumors
This Phase I/II study tests LM-101, a new injection, in adults with advanced solid cancers that have already been treated and kept growing. It aims to see how safe it is and whether it can shrink tumors or help people live longer.
Guangzhou, GuangdongAges 18 years+ - NCT07549022RecruitingPhase 1/Phase 2
Testing BMS-986504 for Unresectable Nerve Sheath Tumors
This study tests whether a new drug called BMS-986504 is safe and effective for treating malignant peripheral nerve sheath tumors (MPNST) that cannot be surgically removed. The drug targets a specific genetic change (MTAP deletion) found in these tumors.
Cleveland, OhioAges 12 years+ - NCT05690581RecruitingPhase 1
CM369 for advanced cancers with special immune marker in tumors
This Phase 1 study tests how safe and tolerable CM369 is in people with advanced solid tumors or blood cancers. It also looks at how the drug behaves in the body and whether it can help shrink or control cancer, especially when a tumor marker called CCR8 is present.
Guangzhou, GuangdongAges 18–75 - NCT06758713RecruitingPhase 1
Gene-therapy treatment for blood cancers: safety and early effects
This trial tests a new kind of gene therapy (fourth-generation CAR-T) for several types of blood cancers including lymphoma, leukemia, and myeloma. It aims to see if the treatment is safe and starts to work against the cancer.
Guangzhou, GuangdongAges 18–75 - NCT07490626Recruiting
Home paracentesis for cancer-related fluid buildup
This study tests whether patients with cancer-related belly fluid can safely have their fluid drained at home instead of at a clinic. If it works, it could make treatment more convenient and comfortable.
Salt Lake City, UtahAges 18 years+ - NCT06649708RecruitingPhase 1/Phase 2
Study of HX044 for advanced solid tumors
This trial tests an experimental drug called HX044 for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it is safe and helps shrink tumors.
Blacktown, New South WalesAges 18–75 - NCT07486713RecruitingPhase 4
Olutasidenib drug interaction study for IDH1 mutation cancers
This trial tests how olutasidenib interacts with other drugs in people with cancers that have an IDH1 mutation, like certain leukemias or brain tumors. Participation may help determine the best way to take this treatment safely.
Orange, CaliforniaAges 18 years+
Hear when a new Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for malignancy?
- Yes. Clin2 currently lists 1,543 recruiting malignancy studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a malignancy trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a malignancy trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.